Vogelmeier, Claus F.
Worth, Heinrich
Buhl, Roland
Criée, Carl-Peter
Gückel, Eva
Kardos, Peter
Article History
Received: 17 January 2022
Accepted: 13 April 2022
First Online: 2 May 2022
Declarations
:
: DACCORD was approved by the ethics committee of the University of Erlangen-Nuremberg, Germany. All patients provided written informed consent prior to inclusion in the study.
: Not applicable.
: CV reports personal fees from Novartis during the conduct of this study. Outside the submitted work he reports personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, MedUpdate, Menarini, and Nuvaira. HW reports personal fees from Novartis during the conduct of this study. Outside the submitted work he reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Omron, and Takeda. RB reports personal fees from Novartis during the conduct of this study. Outside the submitted work he reports personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva, grants from Novartis, and grants and personal fees from Boehringer Ingelheim, GlaxoSmithKline, and Roche. CPC reports personal fees from Novartis during the conduct of this study. Outside the submitted work he reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Omron, Sanofi, and Takeda. EG is employed by Novartis, the sponsor of the study. PK reports personal fees from Novartis during the conduct of this study. Outside the submitted work he reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, MSD, and Sanofi.